INSIGHT 01Fact
48%
48% of applications are in Pharmaceuticals
1,274 applications in this field, 1,137 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsPharmaceuticals and diagnostics
COMPANY PATENT INTELLIGENCE
Explore drug-delivery and pharmaceutical technologies through the selected F. Hoffmann-La Roche legal entity.
≥2,960docs
247 per month · peak 2025-03 (446)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
48%
1,274 applications in this field, 1,137 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
INSIGHT 02Fact
15%
Measurement, machine tools, handling and chemical engineering together reach 425, mostly production-line, equipment and inspection filings.
Method: Four fields added ÷ all applications (fields may overlap)
2,673 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 140 | 109 | 224 | 128 | 126 | 116 | 88 | 79 | 86 | 84 | 89 | 81 |
| Biotechnology | 99 | 89 | 138 | 91 | 88 | 97 | 64 | 75 | 71 | 78 | 74 | 60 |
| Organic fine chemistry | 62 | 59 | 138 | 70 | 69 | 60 | 53 | 31 | 47 | 35 | 38 | 38 |
| Medical technology | 47 | 51 | 63 | 39 | 39 | 42 | 37 | 45 | 37 | 31 | 39 | 40 |
| Measurement | 19 | 20 | 46 | 27 | 28 | 22 | 36 | 28 | 18 | 29 | 18 | 14 |
| Analysis of biological materials | 20 | 17 | 38 | 22 | 23 | 21 | 22 | 14 | 20 | 20 | 16 | 15 |
| Computer technology | 14 | 9 | 15 | 12 | 17 | 20 | 18 | 21 | 12 | 13 | 26 | 8 |
| Chemical engineering | 17 | 9 | 15 | 11 | 14 | 5 | 6 | 9 | 3 | 6 | 5 | 4 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 19 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 3 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 1 of 1 entities
仅观察豪夫迈·罗氏这一已核验法人,relation=other 不将其误标为上市控股母公司。标准名来自原始申请人交叉核对;不扩展至 Genentech、诊断子公司或中外制药的独立文献。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250001031A1
The abstract places particle counting within a sterilisation tunnel of a medicament filling system. Claim 1 combines a probe, holder, transverse linear guide, bogie moving along the conveyor direction and scanner controller. The reading concerns coordinated inspection hardware and transport geometry in pharmaceutical manufacturing.
US20250034538A1
The abstract proposes fusion proteins targeted to the central nervous system. Claim 1 requires a lysosomal protein, an antibody Fc region and a transferrin-receptor-targeting antibody fragment with monovalent binding. This identifies an integrated protein and receptor-binding design; the publication alone does not establish brain delivery efficiency or clinical benefit.
41 publication offices · 2,960 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Invention grant
Compositions and methods of treating lupus nephritis
HOFFMANN LA ROCHE
BiotechnologyPharmaceuticals
Invention grant
Compositions and methods of treating lupus nephritis
HOFFMANN LA ROCHE
BiotechnologyPharmaceuticals
Invention publication
Assessment of chronic liver disease
ROCHE DIAGNOSTICS GMBH / HOFFMANN LA ROCHE
Analysis of biological materialsBiotechnology
Invention publication
Compositions and methods for candida species detection
HOFFMANN LA ROCHE / ROCHE DIAGNOSTICS GMBH
Biotechnology
Invention publication
Optimization and personalization of therapeutic protocols
ROCHE DIABETES CARE GMBH / HOFFMANN LA ROCHE
Medical technology
Invention publication
Methods of screening for multispecific antibodies
HOFFMANN LA ROCHE
Biotechnology
Invention publication
Solid formulations comprising inhibitors of k-Ras proteins having G12C mutations and methods of making
GENENTECH INC / HOFFMANN LA ROCHE
Pharmaceuticals
Invention publication
Switch receptor
HOFFMANN LA ROCHE
Pharmaceuticals
Invention publication
Mixed triblock copolymer membrane compositions and methods for nanopore sequencing
HOFFMANN LA ROCHE / UNIV OF BASEL
Chemical engineering
Invention publication
Bispecific antibodies targeting BCMA and CD28
HOFFMANN LA ROCHE
BiotechnologyPharmaceuticals
Invention publication
Computer-implemented method for quality assurance of in vitro diagnostic analyzers
HOFFMANN LA ROCHE / HITACHI HIGH TECH CORP
Medical technology
Invention grant
Digital biomarker
HOFFMANN LA ROCHE
Medical technology
Invention grant
CGAS inhibiting triazolopyrimidone derivatives
HOFFMANN LA ROCHE
Organic fine chemistryPharmaceuticals
Invention grant
Composition comprising recombinant Gplbα receptor protein
HOFFMANN LA ROCHE
Analysis of biological materialsBiotechnology
Invention grant
Connected machine-learning models with joint training for lesion detection
GENENTECH INC / HOFFMANN LA ROCHE
Computer technology
Other
Safety unit for analyte sensor
HOFFMANN LA ROCHE
Electrical machinery, apparatus, energyMedical technology
Other
Method for immunosensing on a lipid layer using magnetic tunnel junctions ii
HOFFMANN LA ROCHE
Electrical machinery, apparatus, energyAnalysis of biological materialsBiotechnologyMicro-structural and nano-technology
Other
Removal of excess oligonucleotides from a reaction mixture
HOFFMANN LA ROCHE
Biotechnology
Other
Method and auxiliary device for removing gas and/or gas bubbles from a liquid medicament stored in a reservoir
HOFFMANN LA ROCHE
Medical technologyChemical engineering
Invention publication
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
HOFFMANN LA ROCHE
Pharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
F. Hoffmann-La Roche AG
Configured aliases: F. Hoffmann-La Roche Ltd · HOFFMANN LA ROCHE · F HOFFMANN LA ROCHE AG
Original review note: 仅观察豪夫迈·罗氏这一已核验法人,relation=other 不将其误标为上市控股母公司。标准名来自原始申请人交叉核对;不扩展至 Genentech、诊断子公司或中外制药的独立文献。
Review evidenceFound a wrong attribution or number? Tell us